A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

Also called NCT03697109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03697109
Other papers using this trial's data
  • Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study The lancet. Diabetes & endocrinology, 2026-04 DOI, PubMed 41730814, PMC13220893 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03697109. Randomized; triple masking; primary purpose treatment. Start 2018-11-15 (actual); primary completion 2024-04-08 (actual). Results posted on 2025-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Acronym
GRACE
Condition
Cushing Syndrome
Intervention (Drug)
Relacorilant
Intervention (Other)
Placebo
Lead sponsor
Corcept Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03697109
Content hash
12f194b3d21e89c0f80e089472f8d433f06519ee1907611340a789025968daa6